Home > Insider Trading > Filing (0001246360-14-004749)

Filing Details

Accession Number:: 0001246360-14-004749
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-19 17:56:09
Reporting Period:: 2014-12-17

Filing Date:: 2014-12-19
Accepted Time:: 2014-12-19 17:56:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532218	K Sanj Patel	33 Hayden Ave Lexington MA 02421	President & Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-17	13,536	$1.70	14,567	No	4	M	Direct
Common Stock	Acquisiton	2014-12-17	5,016	$3.52	19,583	No	4	M	Direct
Common Stock	Acquisiton	2014-12-17	31,448	$23.00	51,031	No	4	M	Direct
Common Stock	Disposition	2014-12-17	5,016	$87.25	46,015	No	4	S	Direct
Common Stock	Disposition	2014-12-17	13,536	$87.55	32,479	No	4	S	Direct
Common Stock	Disposition	2014-12-17	4,488	$87.26	27,991	No	4	S	Direct
Common Stock	Disposition	2014-12-17	26,960	$90.06	1,031	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-17	13,536	$0.00	13,536	$1.70
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-17	5,016	$0.00	5,016	$3.52
Common Stock	Stock Option (Right to Buy)	Disposition	2014-12-17	31,448	$0.00	31,448	$23.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,512	2021-05-25	No	4	M	Direct
0	2018-09-24	No	4	M	Direct
136,052	2021-12-20	No	4	M	Direct

Footnotes

The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 3, 2014.
The Stock Option granted the reporting person an option to purchase 108,052 Shares. 25% of such Shares vested and became exercisable on 5/25/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
The Stock Option granted the reporting person two options on 09/24/2008. These options are combined for reporting purposes herein. The first option was to purchase 99,017 Shares. 25% of such Shares vested and became exercisable on 6/23/2009, and 1/36 of the remainder of such Shares vested and became exercisable monthly thereafter. The second was an option to purchase 33,005 Shares. 25% of such Shares vested and became exercisable on 9/24/2010, and 1/36 of the remainder of such Shares vested and became exercisable monthly thereafter.
The Stock Option granted the reporting person an option to purchase 167,500 Shares. 25% of such Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $87.21 to $87.27. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $87.17 to $87.77. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in a trade through a broker-dealer.